MIGDAL HA'EMEQ, Israel, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq: ENZY ) (the "Company") today announced the pricing of a registered secondary public offering. The size of the offering has been increased to 4,698,857 ordinary shares at a price of $28.00 per share. The underwriters have a 30-day option to purchase up to an additional 704,828 ordinary shares at the public offering price. All of the shares are being sold by the Company's shareholders. The Company will not receive any proceeds from the sale of these shares. The offering is expected to close on March 5, 2014, subject to customary closing conditions.
BofA Merrill Lynch and Jefferies LLC are serving as joint book-running managers for the offering. Wells Fargo Securities, LLC is serving as lead manager for the offering. Canaccord Genuity Inc. and Wedbush Securities Inc. are serving as co-managers for the offering.
The offering is being made solely by means of a prospectus, copies of which may be obtained from either: BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attention: Prospectus Department or emailing dg.prospectus_requests@baml.com ; or Jefferies LLC, 520 Madison Ave, 12th Floor, New York, NY 10022, 877-547-6340, email: Prospectus_Department@Jefferies.com .
A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies.
ICR Katie Turner 646-277-1228
